Title: Inhibition of aquaporin-1 prevents myocardial remodeling by blocking the transmembrane transport of hydrogen peroxide

Authors: Virginie Montiel¹, Ramona Bella¹, Lauriane Y.M. Michel¹, Hrag Esfahani¹, Delphine De Mulder¹, Emma L. Robinson², Jean-Philippe Deglasse³, Malte Tiburcy^{13,14}, Pak Hin Chow⁶, Jean-Christophe Jonas³, Patrick Gilon³, Benjamin Steinhorn⁴, Thomas Michel⁴, Christophe Beauloye⁵, Luc Bertrand⁵, Charlotte Farah¹, Flavia Dei Zotti¹, Huguette Debaix^{16,17}, Caroline Bouzin⁷, Davide Brusa⁸, Sandrine Horman⁵, Jean-Louis Vanoverschelde⁵, Olaf Bergmann⁹, Dimitri Gilis¹⁰, Marianne Rooman¹⁰, Alessandra Ghigo¹¹, Simonetta Geninatti-Crich¹², Andrea Yool⁶, Wolfram.H. Zimmermann^{13,14,15}, H. Llewelyn Roderick², Olivier Devuyst^{16,17}, Jean-Luc Balligand^{1*}.

Affiliations:

(¹) Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium

(²) Laboratory of Experimental Cardiology, Department of Cardiovascular Sciences, KULeuven, 3000 Leuven, Belgium

(³) Institute of Experimental and Clinical Research (IREC), Endocrinology, Diabetes and Nutrition (EDIN), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium

(⁴) Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 2115, USA

(⁵) Institute of Experimental and Clinical Research (IREC), Pole of Cardiovascular Research (CARD), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium

(⁶) Adelaide Medical School, University of Adelaide, Adelaide, SA 5000, Australia

(⁷) 2IP-IREC Imaging Platform, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium

(⁸) Flow Cytometry Platform, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium

(⁹) Center for Regenerative Therapies Dresden, Technische Universität Dresden, 01062 Dresden, Germany and Department of Cell and Molecular Biology, Karolinska Institutet, 171 77 Stockholm, Sweden

(¹⁰) Computational Biology and Bioinformatics (3BIO-BioInfo), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium

(¹¹) Molecular Biotechnology Center, Università di Torino, 10124 Torino, Italy

(¹²) Molecular Biotechnology and Health Sciences, Università di Torino, 10124 Torino, Italy

(¹³) Institute of Pharmacology and Toxicology, University Medical Center Göttingen, 37075 Göttingen, Germany

(¹⁴) DZHK (German Center for Cardiovascular Research), partner site Göttingen, 37075 Göttingen, Germany

(¹⁵) Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, 37075 Göttingen, Germany

(¹⁶) Institute of Experimental and Clinical Research (IREC), Nephrology (NEFR), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium

(¹⁷) Institute of Physiology, University of Zürich, CH 8057 Zürich, Switzerland

*Corresponding author. Email: jl.balligand@uclouvain.be.

Overline: CARDIAC HYPERTROPHY

Abstract: Pathological remodeling of the myocardium has long been known to involve oxidant signaling, but strategies using systemic antioxidants have generally failed to prevent it. We sought to identify key regulators of oxidant-mediated cardiac hypertrophy amenable to targeted pharmacological therapy. Specific isoforms of the aquaporin water channels have been implicated in oxidant sensing, but their role in heart muscle is unknown. RNA sequencing from human cardiac myocytes revealed that the archetypal *AQP1* is a major isoform. *AQP1* expression correlates with the severity of hypertrophic remodeling in patients with aortic stenosis. The AQP1 channel was detected at the plasma membrane of human and mouse cardiac myocytes from hypertrophic hearts, where it colocalized with NADPH oxidase-2 (NOX2) and caveolin-3. We show that hydrogen peroxide (H₂O₂), produced extracellularly, is necessary for the hypertrophic response of isolated cardiac myocytes and that AQP1 facilitates the transmembrane transport of H₂O₂ through its water pore, resulting in activation of oxidant-sensitive kinases in cardiac myocytes. Structural analysis of the amino acid residues lining the water pore of AQP1 supports its permeation by H₂O₂. Deletion of *Aqp1* or selective blockade of the AQP1 intra-subunit pore inhibited H₂O₂ transport in mouse and human cells and rescued the myocyte hypertrophy in human induced pluripotent stem cell-derived engineered heart muscle. Treatment of mice with a clinically approved AQP1 inhibitor, Bacopaside, attenuated cardiac hypertrophy. We conclude that cardiac hypertrophy is mediated by the transmembrane transport of H₂O₂ by the water channel AQP1, and that inhibitors of AQP1 represent new possibilities for treating hypertrophic cardiomyopathies.

One Sentence Summary: Pharmacological inhibition of AQP1 prevents H₂O₂ transport and hypertrophy of cardiac myocytes.

Introduction

Myocardial remodeling is a prequel to heart failure. It involves profound structural and functional alterations in cardiac tissue driven by hemodynamic stress, inflammation and neurohumoral stimulation. Hypertrophy of cardiac myocytes largely contributes to alterations in ventricular compliance that, combined with gene expression reprogramming and loss of contractility, leads to loss of diastolic and systolic functions (1, 2). Oxidative stress is a common pathogenic feature underlying these phenomena, but the actual identity, sources and distribution of the reactive oxygen species (ROS) involved in different myocardial cell types remain unclear. This may explain the failure of previous clinical trials in which antioxidants have been applied systemically (3, 4), pointing to the need for a more detailed understanding of ROS signaling and regulation in the myocardium.

There are many potential sources of ROS in the stressed myocardium, either from paracrine sources (e.g. from inflammatory cells) or from within cardiac myocytes themselves. Mitochondria, xanthine oxidoreductase, NADPH oxidases as well as uncoupled nitric oxide synthases (NOS) all are recognized producers of ROS in different compartments of cardiac myocytes. Recent advances have highlighted the pathogenic role of ROS and nitrosating species in the development of heart failure (5, 6), and specifically of hydrogen peroxide (H₂O₂) in cardiac myocytes (7, 8). The identification of key regulators of its distribution, particularly in specific sub-cellular compartments is paramount for the design of targeted therapies.

Aquaporins (AQPs) are a family of water channels with large tissue/cell distribution (9). Several isoforms are expressed in cardiac and vascular tissues, e.g. AQP1, AQP4, AQP7 and AQP8 in the mouse heart (10). Some AQP isoforms may transport other molecules in addition to water, e.g. glycerol for the “aquaglyceroporins” (AQP3, 7, 9 and 10) or ammonia and/or H₂O₂ for the “peroxiporins” (11). The latter include AQP3 (12), AQP8 (13) and AQP9 (14), which were shown to mediate H₂O₂ import and/or signaling in inflammatory or cancer cell lines in vitro. Whether these or other AQP isoforms mediate oxidant signaling in specific cardiac cell types is unknown. No cardiac phenotype has been described so far in mice following knockout of *Aqp8* (15), *Aqp3*, or *Aqp9* (16). Conversely, genetic deficiency in *Aqp1* results in microcardia, with smaller cardiac myocytes compared with wild-type littermates (10, 17). *AQP1* transcripts were also found to be expressed in the stressed human myocardium, including failing hearts (18, 19), without clear identification of the cell type of origin. Moreover, the role of AQP1 in the modulation of cardiac myocyte hypertrophy is unknown, let alone its involvement in H₂O₂ transport in the heart.

Results

Aquaporin-1 expression in mouse and human cardiac myocytes and relationship to myocardial hypertrophy

The mouse heart expresses transcripts for *Aqp1*, *Aqp4*, *Aqp7* and *Aqp8*, as detected by RT-qPCR, as well as the corresponding proteins by immunoblotting (10). However, only AQP1, AQP4 and AQP7 proteins are found in plasma membrane fractions, whereas AQP8 is detected exclusively in cytosolic membrane fractions (10), including the endoplasmic reticulum (19). We first confirmed the expression of AQP1 and AQP4 proteins in isolated adult mouse cardiac myocytes (Fig. 1A and fig. S1A). We next analyzed *AQP* transcripts differentially expressed in human cardiac

myocytes from healthy and hypertrophic hearts (Fig. 1B). Human hypertrophic myocardium expressed genes typically associated with remodeling (*NPPA*, *NPPB*, *MYH7*, *TNNT2*), as expected (fig. S1B). To restrict our analysis to cardiac myocytes, cell-specific RNA was isolated from flow-sorted pericentriolar material 1-positive (PCM1⁺) cardiac myocyte nuclei and the transcriptome was profiled by RNAseq. This approach allows isolation of RNA highly enriched in marker genes and processes that are specific to cardiac myocytes (20). Among all *AQP* isoforms, we found *AQP1* to be actively transcribed in healthy and hypertrophic myocytes (Fig. 1B and fig. S1, C and D). Further analysis restricted to mature RNA by RT-qPCR from the same nuclei revealed *AQP1* to be upregulated in hypertrophic myocytes (Fig. 1, C and D), while other highly expressed *AQP* isoforms (*AQP4*, *AQP7*, *AQP9*) were unchanged (fig. S1, E to G). Gene ontology pathway analysis revealed an enrichment of biological processes related to oxidative stress in cardiac myocytes from hypertrophic myocardium (fig. S1H). We confirmed AQP1 protein expression at the peripheral membrane of human cardiac myocytes in biopsy specimens from patients with or without cardiac hypertrophy (Fig. 1E). Moreover, RT-qPCR analysis of mRNA isolated from biopsy samples from patients with aortic stenosis revealed a positive correlation between *AQP1* mRNA expression and degree of hypertrophy (as measured by pre-operative echocardiography) (Fig. 1F), further suggesting relevance to human pathology.

Attenuated hypertrophy in aquaporin-1-deficient mice

We next used *Aqp1*-deficient mice to test the function of AQP1 in the development of hypertrophy in vivo. Knockout (*Aqp1*^{-/-}), heterozygous (*Aqp1*^{+/-}; with 50% reduction of Aqp1 protein; fig. S2A) and wild-type (*Aqp1*^{+/+}) littermates were either subjected to transverse aortic constriction (TAC) (Fig. 2, A to I) or mini-pump infusion of angiotensin II (Ang II; Fig. 2, J to L). The dose of Ang II (2.0 mg/kg/day for 2 weeks) was selected based on preliminary experiments showing similar hypertrophy at this dose compared with 1.2 or 2.0 mg/kg/day for 4 weeks in this SV129 mouse background. Both TAC and Ang II infusion induced the expected hypertrophic remodeling, including myocyte hypertrophy and interstitial fibrosis in *Aqp1*^{+/+} mice. However, these effects were attenuated in *Aqp1*^{-/-} mice, despite similar trans-stenotic gradients post-TAC (verified by echocardiography, fig. S2B) or similar increases in peripheral blood pressure following Ang II (verified by implanted telemetry in awake mice, fig. S2C). The attenuated cardiac hypertrophy was associated with lower expression of genes characteristic of hypertrophic remodeling, e.g. *Nppb* and *Myh7* (Fig. 2, G and H), as well as decreased immunolabeled COL1A1 protein (Fig. 2F), whole collagen content and

packing/alignment reflected by color hue under polarized light (Fig. 2E). Notably, the heterozygous *Aqp1*^{+/-} mice developed an intermediate phenotype (Fig. 2A), confirmed by histomorphometric measurements (Fig. 2, B to D). While *Aqp1*-deficient mice exhibited milder concentric hypertrophy (Table 1, 2), they did not develop clinical or echocardiographic signs of heart failure up to 9 weeks post-TAC (Table 1).

Rescue of cardiac myocyte hypertrophy by deletion or pharmacologic blockade of aquaporin-1

To verify that AQP1 modulates hypertrophy in the cardiac myocytes themselves, rather than through indirect paracrine effects, we used primary cultured cells isolated from the *Aqp1*-deficient mice and tested their response to a variety of pro-hypertrophic stimuli (Fig. 3, A to E). Cardiac myocytes from *Aqp1*^{+/+} mice developed hypertrophy in response to Ang II (Fig. 3B), endothelin-1 (Fig. 3C), isoproterenol (non-specific beta-adrenergic agonist, Fig. 3D) and phenylephrine (alpha1-adrenergic agonist, Fig. 3E), paralleled with increased incorporation of ¹⁴C-phenyl-alanine reflecting increased protein synthesis (fig. S2D). These hypertrophic effects were abrogated in myocytes from *Aqp1*^{-/-} mice (Fig. 3, A to E and fig. S2D), demonstrating that specific expression of AQP1 in the cardiac myocyte is necessary for the development of hypertrophy in response to neurohumoral agonists.

Because genetic deletion of *Aqp1* may induce changes in other effectors within shared macromolecular complexes that regulate signaling, we repeated these experiments with pharmacologic blockers of AQP1. AQP1 channels are organized in tetramers in the plasma membrane, with water transport being mediated through the individual intra-subunit pore of each monomer, whereas monovalent ions (Na⁺, K⁺) may permeate through the central channel formed by the four monomers (21). We therefore used specific blockers of each form of transport, namely Bacopaside II and AqB011, respectively (Fig. 3F). AqB011, a blocker of the ionic central channel (22), did not influence the hypertrophy of *Aqp1*^{+/-} cardiac myocytes treated with phenylephrine. Conversely, Bacopaside II, a specific blocker of the intra-subunit water pore (23) fully blocked the hypertrophic response in these cells. Together, these data clearly showed that AQP1 contributes to the hypertrophic response of cardiac myocytes through permeability of its water channel.

We next evaluated the impact of *Aqp1* deletion on rapid water transport across the membrane of isolated adult mouse cardiac myocytes. Changes in volume of fluorescently labeled myocytes were used as a surrogate of water-induced swelling and validated by comparison with water proton low-field nuclear magnetic resonance (¹H-NMR) relaxometry (Fig. 3, G and H and fig. S3). Incubation of myocytes in hypo-osmotic (100 mOsm.l⁻¹) buffer induced swelling (Fig.

3G), as well as increased water residence time (Fig. 3H), indicative of rapid water influx in *Aqp1*^{+/+} cardiac myocytes; notably, hypo-osmotic water transit was identical in myocytes from *Aqp1*^{-/-} mice, probably due to compensatory transport by other AQP (e.g., AQP4). Short-term stimulation with phenylephrine in iso-osmotic solution produced minimal swelling of cardiac myocytes (Fig. 3I) which, like hypo-osmotic stress, was not different between genotypes. Therefore, AQP1 is dispensable for the rapid water movements across the membrane of cardiac myocytes, whereas it is necessary for hypertrophy.

Extracellular hydrogen peroxide from NADPH oxidase as mediator of cardiac myocyte hypertrophy

ROS from different sources differentially mediate hypertrophic signaling and/or contractile dysfunction in cardiac myocytes (24). By proximity ligation assays, we observed a co-localization of the p47^{phox} subunit of NADPH oxidase NOX2 with the caveolar coat protein caveolin-3 at the peripheral plasma membrane (Fig. 4A), confirming its confinement to caveolin-enriched membrane fractions (25). Notably, p47^{phox} also colocalized with AQP1 at the peripheral membrane (Fig. 4B). The colocalization signal was increased upon myocyte stimulation with Ang II (Fig. 4B, lower), whereas it was absent in negative control experiments. Of note, the association of p47^{phox} with caveolin-3 after Ang II superfusion was preserved in cardiac myocytes from *Aqp1*^{-/-} mice (Fig. 4A), showing that deletion of AQP1 does not interfere with the assembly of NOX2 subunits necessary for its activation at the membrane. These results suggested a co-localization of AQP1 and NOX2 in the caveolin-3-enriched peripheral membrane, with an increased assembly of functional NADPH oxidase upon treatment with Ang II.

We next tested the involvement of NOX2 as a source of pro-hypertrophic ROS. In adult mouse cardiac myocytes, co-incubation with the pan-NOX inhibitor VAS2870 (26) at a concentration known to preferentially inhibit NOX2 (27) abrogated the hypertrophic response to all four neurohumoral agonists (Fig. 4C), pointing to NADPH oxidase as a main source of ROS for promoting hypertrophy.

Plasmalemma-associated NOX are known to produce superoxide anions in the extracellular space (28), where they are rapidly dismutated to H₂O₂ by the extracellular superoxide dismutase (or SOD3) (29). To confirm the involvement of extracellular H₂O₂ in the hypertrophic response, adult cardiac myocytes from *Aqp1*^{+/+} mice were stimulated with phenylephrine with or without incubation with non-Polyethylene-Glycol (PEG)-ylated (i.e. membrane-impermeable) catalase, followed by measurement of hypertrophy (Fig. 5A). Catalase had no effect on myocyte size when applied

alone, but it fully abrogated induction of hypertrophy by phenylephrine when co-incubated with the latter (Fig. 5A). As expected, no hypertrophy or effect of catalase was observed in *Aqp1*^{-/-} myocytes. Similar effects were observed in neonatal mouse cardiac myocytes (Fig. 5B).

ROS activate specific oxidant-sensitive kinases that relay the pro-hypertrophic signal in cardiac myocytes. Accordingly, we observed an increase in immunoblotted phospho-p38 and phospho-ERK MAP kinases (MAPK) in response to phenylephrine in adult cardiac myocytes from *Aqp1*^{+/+} mice (Fig. 5, C to G). Notably, this increase in ERK phosphorylation was attenuated upon co-incubation of myocytes with extracellular catalase (Fig. 5C). Increases in the phosphorylated active form of both ERK and p38-MAPK were similarly abrogated in myocytes from *Aqp1*^{-/-} myocytes (Fig. 5, D to G). Together these data show that agonist-induced hypertrophy requires AQP1, NADPH oxidase, as well as the extracellular production of H₂O₂ to activate oxidant-sensitive kinases.

Facilitated transport of hydrogen peroxide in cardiac myocytes by aquaporin-1

In addition to water, H₂O₂ permeates specific plant and eukaryotic aquaporins, known as “peroxiporins” (11). To more directly examine the ability of AQP1 to facilitate the transmembrane transport of extracellular H₂O₂, intracellular H₂O₂ was measured in cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice after exposure to extracellular H₂O₂. To this end, cardiac myocytes were loaded with the fluorescent ROS tracer, Dichlorofluorescein Diacetate (DCFDA) and fluorescence monitored after exposure to H₂O₂ at different concentrations. The time-dependent increase in the fluorescent signal was attenuated in *Aqp1*^{-/-} myocytes exposed to 50 or 100 μ M extracellular H₂O₂, compared to *Aqp1*^{+/+} myocytes (Fig. 6, A and B). To verify the identity of the oxidant species as H₂O₂ and its subcellular confinement at the plasma membrane, we repeated experiments in cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice that had been infected with a cardiotropic recombinant Adeno-Associated Virus, type 9 (AAV9) coding for the H₂O₂-specific HyPer3 fluorescent biosensor fused to a caveolae-targeting peptide [derived from the caveolin-interacting sequence of eNOS (30); Fig. 6C]. Application of H₂O₂ induced an increase in the fluorescent signal in cardiac myocytes expressing the HyPer probe. No such change in fluorescence was observed in cardiac myocytes infected with an AAV9 coding for the H₂O₂-insensitive probe, SypHer2, which was used as a negative control for the HyPer probe. Notably, the concentration-dependent increase in H₂O₂-specific fluorescent signal was substantially attenuated in *Aqp1*^{-/-} myocytes compared to *Aqp1*^{+/+} controls (Fig. 6C). Moreover, the increase in fluorescent signal observed in

Aqp1^{+/+} myocytes exposed to extracellular H₂O₂ was also dose-dependently attenuated by pre-incubation with Bacopaside II (Fig. 6D), confirming the involvement of the AQP1 water pore in the facilitated transport of H₂O₂. Stimulation of adult cardiac myocytes with phenylephrine (at concentrations that produce hypertrophy) also increased fluorescence in *Aqp1*^{+/+} myocytes, but not in *Aqp1*^{-/-} myocytes (Fig. 6, E and F). Taken together, these data clearly point to a facilitated transport of H₂O₂ by the water pore of plasma membrane-localized AQP1, a process that is necessary for the hypertrophic response of cardiac myocytes.

Aqp1-dependent induction of pro-fibrotic genes in cardiac myocytes

To gain further insight into the mechanism of regulation of cardiac fibrosis by AQP1, we measured the expression of genes coding for mediators of fibrosis that are known to be sensitive to oxidant stress in isolated cardiac myocytes (31). Upon stimulation with phenylephrine, the abundance of transcripts for *Tgfb2* and *Ctgf*, two major cytokines involved in the paracrine activation of fibroblasts, was clearly attenuated in cardiac myocytes isolated from *Aqp1*^{-/-} mice compared to *Aqp1*^{+/+} controls (fig. S4, A and B). Moreover, when cardiac fibroblasts cultured separately were incubated with medium conditioned by phenylephrine-treated primary cardiac myocytes from the two genotypes, we observed a reduction of COL1A1 protein expression, as well as of ACTA2, indicative of reduced myofibroblast differentiation, in fibroblasts exposed to the secretome of *Aqp1*^{-/-} myocytes compared to *Aqp1*^{+/+} controls (fig. S4, C to F). Therefore, in addition to regulating hypertrophy, AQP1 modulates cardiac myocyte production of pro-fibrotic mediators acting on cardiac fibroblasts in a paracrine fashion.

Permeability of human AQP1 to hydrogen peroxide

To examine the permeability of human AQP1 to H₂O₂, we first aligned its protein sequence and structure with those of *Mus musculus* AQP1 (studied in our experiments above), *Rattus norvegicus* AQP1 and *Homo sapiens* AQP8 (a known “peroxiporin”), the pore sequence of which was included as positive control (fig. S5). The sequence of *Homo sapiens* AQP4 was used as negative control, based on its inability to transport H₂O₂ (32). Residues lining the pore region, e.g. the aromatic/arginine (ar/R) filter region at the extracellular entrance of the pore known to be critical for filter specificity, are identical between mouse, rat and human AQP1, as shown in Fig. 7A. In human AQP8, the key amino acids are conserved but they are located at different positions along the sequence and in the deduced structure.

More precisely, the pore residues comprise a sulfur-containing cysteine residue (Cys189 in AQP1, Cys53 in AQP8) in the vicinity of an arginine (Arg195 in AQP1, Arg213 in AQP8), a histidine (His180 in AQP1, His72 in AQP8), and aromatic phenylalanine residues (Phe56 and Phe24 in AQP1, Phe48 in AQP8); AQP8 contains two additional sulfur-containing residues (Cys208 and Met209). Interestingly, the negative control AQP4 shows some similarity to AQP8 but lacks the two cysteines, which are replaced by a leucine (Leu53) and a serine (Ser211). Analysis of the inter-residue interactions in AQP1 reveals that Cys189 makes polar interactions with Arg195 as well as a sulfur-His interaction with His180, which makes a His- π interaction with Phe56. The latter in turn makes a cation- π interaction with Arg195 and a π - π interaction with Phe24 (Fig. 7A). Similar interactions are identified in rat (identical to mouse) AQP1, as well as in human AQP8 (albeit involving residues at different spatial and sequence positions - see Fig. 7A and fig. S5). Conversely, AQP4 exhibits no cysteine residue in contact with the pore, only a methionine that forms a sulfur-His interaction (Met212-His201), and no sulfur-Arg contact. This structural analysis supports AQP1 permeability to H₂O₂, akin to the peroxiporin AQP8.

To test this hypothesis, we explored the effect of Bacopaside II on the DCFDA fluorescence signal of human erythrocytes (with known high membrane expression of AQP1) exposed to extracellular H₂O₂ (Fig. 7B). Exposure to H₂O₂ dose-dependently increased fluorescence in untreated erythrocytes. By contrast, pre-treatment with Bacopaside II strongly decreased the fluorescence induced by exposure to H₂O₂, showing that native human AQP1 also facilitates the transport of H₂O₂ across erythrocyte membranes through its water channel.

Expression of AQP1 in human iPSC-derived engineered heart muscle and regulation of hypertrophy

We next used human induced pluripotent stem cell (iPSC)-derived engineered heart muscle (EHM) (33) to confirm the role of AQP1 in hypertrophy of human cardiac myocytes. While differentiating into EHM, iPSCs increase their expression of *AQP1* to a level similar to that observed in human adult cardiac muscle (Fig. 7C). Differentiated EHM were treated with norepinephrine for 1 week with or without Bacopaside II (10 μ M). The size of cardiac myocytes dissociated from the EHM was then measured using a validated flow cytometry assay as described previously (33). While norepinephrine produced hypertrophy in the solvent-treated control myocytes, the response was attenuated when Bacopaside II was co-applied (Fig. 7D). Additional parameters of contractility (e.g. force-frequency relationship (Fig. 7E) and contraction/relaxation times (Fig. S6) were unaffected by AQP1 blockade.

Attenuated hypertrophy by pharmacologic blockade of aquaporin-1 in vivo

To determine the applicability of AQP1 blockade as a strategy to block the hypertrophic response in vivo, we tested the effect of a standardized extract of the dried plant *Bacopa monnieri* in a pharmaceutical compound that is available for clinical use (KeenMind) (34) on Ang II-induced hypertrophy. This compound contains about 30% by weight of mixed bacosides, including Bacopaside II (~3% by weight) (35). We used the *Xenopus* oocyte expression system to first confirm the efficacy of the Bacopa extract (BE) to block human AQP1-mediated osmotic water permeability (Fig. 8, A to C). AQP1-expressing oocytes incubated in saline vehicle showed a robust swelling response as a function of time in 50% hypotonic media, whereas oocytes incubated in BE showed a reduction in the swelling rates (Fig. 8A). The dose causing half-maximal block was about 290 µg/ml of BE (Fig. 8B), corresponding roughly to 9.4 µM of Bacopaside II. Trend plots comparing paired swelling rates for each AQP1-expressing oocyte in a first and second swellings assays (Fig. 8C and fig. S7) show that incubation in vehicle saline did not appreciably affect the second swelling response, in contrast to consistent decreases in swelling rate seen after incubation in increasing doses of BE. The inhibitory effect of BE was statistically significant ($P<0.05$) at the two higher doses tested (Fig. 8C), with the highest corresponding to about 15 µM of Bacopaside II. This concentration is in line with the efficient inhibitory concentration of pure Bacopaside II (20 µM) observed in parallel in the same assay (Fig. 8C), as well as on H₂O₂ permeability and hypertrophy in mouse and human cardiac myocytes.

Finally, we tested the efficacy of AQP1 inhibition on the development of hypertrophy in vivo by giving BE in the food of mice submitted to mini-pump infusion of Ang II. Based on previous pharmacokinetic/pharmacodynamic data in rodents, BE was given at 1600 and 2400 mg/kg of body weight 1 week before and during the 14 days of infusion of Ang II until sacrifice. BE alone had no effect on cardiac morphometric indexes in saline-treated mice. In control mice, Ang II infusion reproduced the hypertrophic response as observed previously, but we found that co-treatment with BE dose-dependently attenuated the hypertrophic remodeling, measured as the ventricular mass (Fig. 8D) and myocyte size (Fig. 8E), with a more variable effect on interstitial fibrosis (Fig. 8, F and G).

Discussion

We identified the water channel AQP1 as a critical modulator of the cardiac myocyte hypertrophy that is integral to myocardial remodeling that leads to heart failure. AQP1 is robustly expressed in human cardiac myocytes and its expression correlates with the severity of cardiac hypertrophy in patients undergoing surgery to treat aortic stenosis. Genetic deletion or pharmacologic blockade of AQP1 in mouse and human iPSC-derived cardiac myocytes is sufficient to attenuate hypertrophy induced by neurohormones or hemodynamic stress. This protective effect is due to loss of transmembrane transport of H_2O_2 , but not water, through the intra-subunit pore of AQP1, which is necessary for downstream hypertrophic signaling. Molecular modeling of AQP1 intra-subunit pore and functional studies in erythrocytes verified that human AQP1 mediates a similar transport of H_2O_2 . Administration of standardized extracts of *Bacopa monnieri*, containing Bacopaside inhibitors of the AQP1 intra-subunit pore, attenuated cardiac hypertrophic remodeling in mice. Taken together, these data support the therapeutic potential of AQP1 blockers against myocardial remodeling.

H_2O_2 has been implicated in the hypertrophic response of cardiac myocytes to a number of neurohumoral agonists, and more generally as a signaling molecule in a wide variety of redox-regulated biological events (36). Multiple O_2^- -producing enzymes (NOX2, NOX4, xanthine oxidoreductase, mitochondrial respiratory complexes, nitric oxide synthases, monoamine oxidases) can generate H_2O_2 after O_2^- dismutation in these cells (37); its subcellular distribution has been poorly characterized. In particular, NOX2 is activated by pro-hypertrophic agonists but the enzyme's flavocytochrome subunit transfers electrons across the plasma membrane to produce O_2^- in the extracellular space (28, 38). It had been postulated that H_2O_2 would freely diffuse back into the cell to exert downstream signaling (39), and we now provide evidence for facilitated H_2O_2 transport through AQP1 confined to the same subcellular compartment. Despite our use of VAS2870 at a concentration that preferentially inhibits NOX2 (27), it should be noted that the drug is a pan-NOX inhibitor with potential off-target effects on other isoforms, e.g. on NOX4. However, aside from the low probability of efficient inhibition of NOX4 at the concentration used here, the involvement of NOX4 is unlikely, given the cytosolic localization of this enzyme and its constitutive production of H_2O_2 intracellularly, that contrast with the stimulus dependency and sensitivity to extracellular catalase of the H_2O_2 signals observed here.

Among the 13 known AQP isoforms, AQP3 (12), AQP8 (13), and AQP9 (14) have also been proposed to transport H₂O₂ in heterologous expression systems, akin to specific isoforms of plant AQPs (11). The role of human AQP1 in the facilitated transport of H₂O₂ had not been tested in cells endogenously expressing the native protein.

Structural analysis of human AQP1 supports its ability to transport H₂O₂ as well as water. The diameter of H₂O₂ relative to H₂O, its neutral charge at physiological pH and its dipole moment all are compatible with AQP1 permeation by H₂O₂ (40). Our analysis of the lining of amino acid side chains surrounding the extracellular entrance of the pore reveals the presence of a conserved thiol group (in Cys189 of AQP1), aromatic residues (Phe56, Phe24), a histidine (His180) and an arginine (Arg195) allowing a network of sulfur- π , His- π , cation- π and π - π interactions critical for protein conformation and channel conductance. Sulfur- π and cation- π interactions in the motif may protect the thiol from oxidation (41, 42), while the conformation of the His may change according to its environment and act as a gate. This motif and orientation of aromatic residues close to the entrance of the pore bear a high degree of similarity with the peroxiporin AQP8, but are notably different in AQP4, where a missing cysteine and the absence of the sulfur-Arg-His triad may explain a different sensitivity to oxidation driving conformational changes in the channel. The propensity of the sulfur residues to be oxidized is influenced by the surrounding microenvironment. The thiol group in cysteine and the sulfide group in methionine can interact with aromatic rings of phenylalanine, tyrosine and tryptophan in sulfur-aromatic interactions. These interactions contribute to manipulating the orientation of the aromatic rings and provide protein stability and protection against ROS. The role of sulfur aromatic interactions is likely to be important in biological processes based on the high degree of conservation across members of the same protein family (43). Proteins carrying motifs of tryptophan, phenylalanine, histidine and the sulfur aromatic residues can undergo modifications of these amino acids and modification of the protein structure under the actions of ROS (44). Oxidation of cysteine and methionine results in modification of sulfur-aromatic interactions and is associated with the disruption of native protein conformation and alteration of function (45, 46).

Changes in the interactions between sulfur-His residues may result in changes of the spatial orientation of histidine, a mechanism compatible with the gating control of the channel under H₂O₂-induced stress. A similar mechanism was proposed for the H₂O₂ induced gating of human AQP8 (47). The presence of any cation- π interactions in the motif surrounding the extracellular entrance of the pore may be another important protection factor against oxidation (41). π - π interactions are important for protein folding and play a role in protection from oxidation (48). His- π interactions are similar to cation- π interactions and play a role in the stabilization of the protein structure. Different interactions

with the aromatic rings were observed between the protonated and neutral form of the histidine, with differences related to the protein's biological function (49).

Analysis of the amino acid composition showed high sequence similarity between human and rat AQP1, including the residues lining the pore region. Additionally, the two proteins share the same residues within the motif surrounding the extracellular entrance of the pore. Interesting results were detected in hAQP8, in which Cys53, Cys208 and Met209 belong to a motif that may play a key role in the protection of cells against ROS damage. The analysis of the sulfur-aromatic-arginine-histidine motif close to the entrance of the pore showed a very high degree of similarity between AQP1 and AQP8, in contrast to differences in the position and interactions of the equivalent motif residues in human AQP4. In AQP4, the lack of a cysteine in the motif prevents an interaction between arginine and sulfur residue, thought to be important for regulation of its reactivity (50) which might explain the differences in permeability to H₂O₂.

Therefore, chemical and physical interaction between the cysteine, methionine and histidine residues within this motif unique to the “peroxiporins” may explain protection from oxidative stress allowing permeation of the channel by H₂O₂.

Our structural analysis is supported by the presented evidence for AQP1-dependent transmembrane passage of H₂O₂ in primary mouse cardiac myocytes. The mouse is an appropriate model system, since mouse and human AQP1 are identical in amino acid composition in the pore constriction site and we verified H₂O₂ transport in human erythrocytes. Importantly, osmotically driven rapid water transport is not affected by *Aqp1* deletion in myocytes, suggesting that AQP4, co-expressed in the same cells, compensates AQP1 loss for water movements. However, the fact that AQP4 may not transport H₂O₂ both explains the dependence on AQP1 for hypertrophy and suggests that its transport of H₂O₂, rather than water, is critical for the initiation of hypertrophic signaling. This is corroborated by the abrogation of hypertrophy with extracellular catalase. The observed co-localization of AQP1 with NOX2 and specific receptors in caveolae-enriched membrane fractions would facilitate localized signaling to effectors, such as ROS-sensitive kinases (51) that in turn relay the signal to induction of a hypertrophic response. This does not exclude the participation of cardiac AQP1 (and other AQP isoforms, e.g. AQP4) in water exchanges at later stages of tissue remodeling. Myocardial fibrosis may also result from H₂O₂ signaling in myocytes with oxidative upregulation and paracrine release of pro-fibrotic factors (31), such as TGFB2 and CTGF as observed here, with subsequent activation of collagen production by neighboring fibroblasts. AQP1 may also “channel” the H₂O₂ signal from other cells surrounding cardiac myocytes, such as endothelial and inflammatory cells.

Neuroendocrine stimulation, hemodynamic stress and aging all converge to produce concentric hypertrophic remodeling, that ultimately may lead to altered diastolic (and later, systolic) dysfunction and heart failure (52). Despite less concentric hypertrophy, *Aqp1*-deficient mice did not develop signs of heart failure, suggesting compensatory adaptive mechanisms. *Aqp1*^{-/-} mice may present hypovolemia secondary to polyuria that they normally compensate with a higher water intake (10, 53). However, afterload (i.e. blood pressure by telemetry and post-TAC gradients) was strictly controlled in our experimental mice. Previous studies in mice had shown that cardiac hypertrophy is dispensable to sustain the hemodynamic overload after TAC (54). Notably, human EHM also maintained their contractility despite AQP1 blockade and inhibition of hypertrophy. Therefore, AQP1 inhibition may be a viable treatment of some forms of hypertrophic cardiomyopathies.

Our use of the *Bacopa monnieri* extract (KeenMind) with its newly validated inhibitory effects on the human AQP1 intra-subunit channel extends the applicability and efficacy of this pharmacological approach in vivo. Extract of the water hyssop *Bacopa monnieri* (also known as brahmi) is an ancient Ayurvedic remedy used to improve memory and treat anxiety and depression (55). A meta-analysis of human clinical studies in which *Bacopa monnieri* was administered over several months indicated improvements in response time, attention, and possibly memory (56). Serious adverse events were not noted; lesser side effects included dry mouth and diarrhea. Previous randomized and controlled clinical trials with the same *Bacopa* extract had established its efficacy to improve the course of several neurodegenerative diseases associated with increased oxidant stress, although a mechanistic connection with AQP1 had not been identified (57). Beneficial outcomes ascribed to brahmi are consistent with the block of AQP1 channels as being one of the potential mechanisms of action, but additional effects on other targets are likely, due to the complexity of the bacopaside molecule. Bacopasides administered in vivo are thought to exert effects via diverse metabolites as well as the original structures.

We chose the *Bacopa* extract rather than bacopaside II in our experiments due to cost/availability of the pure extract. Bacopaside II was shown to reversibly block AQP1 but not AQP4 water channel activity, without cytotoxicity (23). In silico docking based on the structure for human AQP1 (PDB ID. 1FQY; available at NCBI Structure) indicated an energetically favored binding site (-9.3 Kcal/mol) that allowed bacopaside II to effectively occlude the intrasubunit water pore (23). Polar sugar groups of the bacopaside II molecule appeared to nest well into the intracellular vestibule of the AQP1 (but not AQP4) water pore (fig. S-8). Candidate AQP1 residues in the binding pocket might include serine 71 and tyrosine 97, but these remain to be confirmed (23). Bacopaside II is classified as a triterpene glycoside,

characterized by a hydrophobic terpene structure presumed to facilitate transmembrane entry, and three linked saccharides (arabinofuranosyl—glucopyranosyl—glucopyranoside) that appear to serve as the AQP1-binding ligand (fig. S8B). AQP1 water channel activity showed half-maximal block after 0.5 h preincubation with bacopaside II, and maximum block by 1.3 h (23). Other AQP1 ligands such as AqB013, AqB011 and AqF026, also are postulated to bind intracellularly (22, 58, 59) and have similarly slow rates for the onset of block, supporting the proposed intracellular site of action for bacopaside II. Theoretical considerations note shortcomings of bacopaside II as a therapeutic agent, in that it exceeds Lipinski's Rule of Five limits for size, hydrophobicity, and hydrogen bond sites. However, using bacopaside II as a lead compound, ongoing work is exploring polysaccharides as possible endogenous modulators of AQP channels, which could offer new lines of therapeutics not previously considered.

Despite our observation of an anti-hypertrophic effect of Bacopaside in mice and iPSC-derived human cardiac myocytes, similar protective properties against myocardial remodeling remain to be demonstrated in patients. This can be prospectively tested with this low-cost, standardized, and clinically available extract. Altogether, our studies open the way to complement the therapeutic armamentarium with specific blockers of AQP1 for the prevention of adverse remodeling in cardiovascular diseases leading to heart failure.

Materials and Methods

Study design

We tested the hypothesis that AQP1 regulates myocardial remodeling by controlling the plasmalemmal transport of H₂O₂ in cardiac myocytes. We compared the hypertrophic and fibrotic response to hemodynamic stress (trans-aortic constriction) and to neurohormonal stimuli in vivo by quantitative histomorphometry between *Aqp1*-deficient mice and their wild-type littermates. We used primary adult cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice to compare their hypertrophic response to neurohormonal stimuli in vitro, as well as their transmembrane passage of H₂O₂. Similar experiments were repeated in human iPSC-derived engineered heart muscle and human erythrocytes expressing native human AQP1. The effect of Bacopaside extracts that inhibit AQP1 was measured on hypertrophy and H₂O₂ transport in the same models.

The number of animals in experimental studies using adult mice was calculated based on a Bayesian principle of non-informative a priori, i.e. supposing a p=0.5 on the probability of an experimental response, a minimum of 5 animals per group need to be considered to maintain a basis of 5% on the type I error. For in vitro experiments, primary isolates

were obtained from at least 3 independent preparations from 3 different animals (N). Cell measurements were obtained from >200 cells per animal (12-14 myocytes measured in each of 6 randomly chosen microscopic fields in each of 3 histological sections/heart) and 30-70 cells per condition (3-7 myocytes measured in each of 10 randomly taken photomicrographs from each in vitro culture). All experiments were conducted in a blinded fashion, i.e. the operators treating mice or cells and assessing the endpoints were blinded to the mouse genotype. Before unblinding, raw data were examined for normal distribution using the Shapiro-Wilk test; when outliers were identified, they were excluded from analysis if justified based on confirmed technical failure in parameter acquisition. All experiments on *Aqp1*^{-/-} mice were compared to their *Aqp1*^{+/+} littermate controls. Individual subject-level data are reported in data files S1 and S2.

Animals

Breeding pairs of heterozygous *Aqp1*^{+/-} mice in the Sv129 background were obtained from Dr. O. Devuyst (Division of Nephrology, UCLouvain, Belgium). Heterozygous mice were crossbred to obtain homozygous *Aqp1*^{-/-} mice and their *Aqp1*^{+/+} littermate controls. All studied mice were at least 16 weeks old at the time of banding and age-matched between genotypes. Experimental procedures, including aortic banding, minipump infusion of Angiotensin II, echocardiographic, telemetry measurements and isolation of isotypic primary cells, as well as measurements of remodeling parameters are described in Supplementary materials. All protocols were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and the European Directive 2010/63/EU and were approved by local ethical committees.

Oxidation of caveolae-targeted HyPer3 by H₂O₂

Fluorescence measurements were performed with the H₂O₂-specific HyPer-3 fluorescent reporter. The first 97 amino acids of eNOS- which are responsible for the protein's targeting to the caveolae- were fused to the N-terminus of HyPer3 with the NEBuilder HiFi DNA assembly system (New England Biolabs). The resultant cDNA was sub-cloned into an AAV expression vector (Stratagene), where expression was driven by the CMV promoter. This construct was then packaged into AAV9 viral particles by the Children's Hospital Boston Viral Vector Core. The cDNA coding the SyPher2 probe, that is insensitive to H₂O₂ was processed similarly to serve as control for the HyPer3 probe. *Aqp1*^{+/+}

and *Aqp1*^{-/-} mice were infected with approximately 5X10¹¹ genome copies of virus via retro-orbital injection. After five weeks of infection, cardiac myocytes were isolated as described above, and plated on coverslips. After a few hours or overnight culture, the coverslip was mounted in a chamber maintained at 37 °C and placed on the stage of an inverted microscope equipped with a 40X oil immersion objective. The cells were perfused at a flow rate of ~1 ml/minute with a bicarbonate-buffered Krebs solution containing 120 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl₂, 24 mM NaHCO₃, 1 g/l BSA (Fraction V, Roche) and 10 mM glucose. This solution was continuously gassed with O₂/CO₂ (94/6) to maintain the pH around 7.4. The fluorescence ratio of HyPer3 was measured every 30 s after double excitation, at 480 and 400 nm, using an emission filter centered at 535 nm. After 10 minute perfusion, cardiac myocytes were exposed to a stepwise increase in hydrogen peroxide concentration (7.5 min steps at 1, 2.5, 5, 10 and 15 μM H₂O₂). To allow comparison between experiments and genotypes, the fluorescence ratio of each cell was normalized to the initial ratio measured during the first 2 minutes. After exclusion of cardiac myocytes (from *Aqp1*^{+/+} or *Aqp1*^{-/-} mice) that detached from the coverslip during the experiment or that displayed no HyPer3 response to 15 μM H₂O₂ because of too low expression of the sensor, 10 out of 18 cells from 6 *Aqp1*^{+/+} mice and 10 out of 14 cells from 6 *Aqp1*^{-/-} mice were used to compute the mean trace.

Preparation of Engineered Heart Muscle (EHM) from human iPS cells

Human iPSC-derived cardiac myocytes. Human cardiac myocytes were derived from the TC1133 line [Lot Number: 50-001-21 from LiPSC GR1.1 line reported in (60)] by directed differentiation according to Tiburcy *et al.* (33) with slight modifications. Briefly, pluripotent stem cells (PSCs) were plated at 1.3×10⁴ cells/cm² on 1:120 Matrigel in phosphate-buffered saline (PBS)–coated plates and cultured in StemMacs iPS-Brew XF (Miltenyi Biotec) for 4 days. To induce cardiac differentiation cells were rinsed with Roswell Park Memorial Institute (RPMI) medium and then treated with RPMI, 2% B27 minus insulin, 200 μmol/L l-ascorbic acid-2-phosphate sesquimagnesium salt hydrate (Sigma-Aldrich), 9 ng/mL Activin A (R&D Systems), 5 ng/mL BMP4 (R&D Systems), 1 μmol/L CHIR99021 (Stemgent), and 5 ng/mL FGF-2 (Peprotech) for 3 days. Following another wash with RPMI medium, cells were cultured from day 4 to 10 with 5 μmol/L IWP4 (Stemgent) followed by RPMI, 2% B27, 200 μmol/L l-ascorbic acid-2-phosphate sesquimagnesium. Cardiac myocytes were metabolically purified by glucose deprivation from day 13 to

17 in RPMI without glucose (Thermo Fischer), 2.2 mmol/L sodium lactate (Sigma-Aldrich), 100 μ mol/L β -mercaptoethanol (Sigma-Aldrich), 100 U/mL penicillin, and 100 μ g/mL streptomycin.

EHM generation. Defined, serum-free EHM was generated from high purity cardiomyocytes (>95% Actinin-positive) and human foreskin fibroblasts (ATCC) at a 70/30% ratio as previously described (33). The cells were reconstituted in a mixture of pH-neutralized medical grade bovine collagen (LLC Collagen Solutions, 0.4 mg/EHM), concentrated serum-free medium (2x RPMI, 8% B27 without insulin, 200 U/ml penicillin, and 200 μ g/ml streptomycin) and cultured for 3 days in Iscove-Medium with 4% B27 without insulin, 1% non-essential amino acids, 2 mmol/l glutamine, 300 μ mol/l ascorbic acid, 100 ng/ml IGF1 (AF-100-11), 10 ng/ml FGF-2 (AF-100-18B), 5 ng/ml VEGF165 (AF-100-20), 5 ng/ml TGF- β 1 (AF-100-21C; all growth factors are from Peprotech), 100 U/ml penicillin, and 100 μ g/ml streptomycin. After a 3-day condensation period, EHM were transferred to flexible holders for auxotonic loading and cardiomyocyte maturation as previously described (61). Treatment with l-Norepinephrine hydrochloride (Sigma-Aldrich, prepared in distilled water containing 200 μ mol/L l-ascorbic acid-2-phosphate sesquimagnesium salt hydrate) and Bacopaside II (Sigma-Aldrich, 10 mM stock prepared in methanol) was initiated on week 3 of EHM maturation. EHMs were treated with indicated concentrations for 7 days.

Analysis of contractile function. Contraction experiments were performed under isometric conditions in organ baths at 37 °C in gassed (5% CO₂/95% O₂) Tyrode's solution (containing: 120 NaCl, 1 MgCl₂, 0.2 CaCl₂, 5.4 KCl, 22.6 NaHCO₃, 4.2 NaH₂PO₄, 5.6 glucose, and 0.56 ascorbate; all in mmol/L). EHM were electrically stimulated at 1.5 Hz with 5 ms square pulses of 200 mA. EHMs were mechanically stretched at intervals of 125 μ m until the maximum systolic force amplitude (force of contraction; FOC) was observed according to the Frank-Starling law. Force-frequency measurements were performed at EC₅₀ calcium concentrations determined individually for each EHM.

Flow cytometry hypertrophy assay. EHMs were digested in collagenase 1 solution (2 mg/mL in calcium-containing PBS in the presence of 20% fetal bovine serum) at 37 °C for 90 minutes. EHM were then washed with PBS (without calcium) and further incubated in Accutase (Millipore), 0.0125% Trypsin (Life Technologies), 20 μ g/mL DNase (Calbiochem) for 30 minutes at room temperature. Cells were then mechanically separated and single cell suspensions were obtained by passing the cells through a 70 μ m cell strainer. Cell were fixed in with 70% ice-cold ethanol and stained for sarcomeric α -actinin (Sigma-Aldrich) and Hoechst-33342 (Life Technologies, 10 μ g/ml).

The following gating strategy was applied, as described previously (33) to assess cardiac myocyte volume: (i) gating of cells based on forward scatter area (FSC-A) and sideward scatter area (SSC-A), (ii) gating of live cells (nuclear DNA content), (iii) gating of single cells (based on DNA signal width), (iv) gating of actinin-positive cardiac myocytes, and (v) assessment of cardiac myocyte size based on median FSC-A. Cells were run on a LSRII SORP Cytometer (BD Biosciences) and analyzed using DIVA software. At least 10,000 live cells were analyzed per sample.

Myocardial samples from patients

Human endomyocardial biopsies from aortic stenosis patients were obtained during surgery from patients suffering of aortic stenosis (n=26) in accordance with the local ethics committee (Comité éthique hospitalo-facultaire des Cliniques Universitaires St Luc, Brussels, Belgium) with signed informed consent obtained prior to surgery. Cardiac biopsies were immediately frozen in liquid nitrogen and stored at -80°C. For cardiac myocyte isolated nuclei, human heart specimens from hypertrophic and healthy myocardial tissue were provided by the Department of Forensic Medicine in Stockholm, Sweden. Ethical permissions were obtained from local ethical committees. Individual patient details are listed in table S1. All procedures for immunohistochemistry, cardiac myocyte nuclear isolation and RNA analysis are described in Supplementary materials.

Structural analysis of AQP_s

The sequence and structure of the target aquaporin (P29972, PDB code 4CSK) were aligned with the sequence and structure of other mammalian aquaporins sharing at least 40 % identity with the target using PDBeFOLD (62). For the proteins with no experimental structure in the Protein Databank (63), the structures were modeled using the comparative modeling webserver Swiss-Model (64). Analysis of the amino acids lining the pore was performed using the web-based resource Pore walker (65), whereas analysis of solvent accessibility and of interactions were performed for each protein structure using the MuSiC suite (66), Protein Interaction calculator (PIC) web server (67) and an in-house program (68). Pymol was used as a visualization tool of the protein structure (The PyMOL molecular Graphic System, version 2.0 Schrödinger, LLC).

Statistical analysis.

All results of continuous variables are expressed as mean $\pm$ SEM. Raw data were first analyzed to confirm their normal distribution and then analyzed by unpaired Student's t-test, one-way ANOVA, two-way ANOVA or two-way ANOVA for repeated measures where appropriate. Dunnett or Sidak correction (one-way ANOVA); Tukey or Sidak correction (two-way ANOVA) were applied to correct for multiple comparisons. In the absence of a normal distribution, a non-parametric Kruskal-Wallis or Mann-Whitney test were used, followed by Dunn's correction for multiple comparisons if appropriate. $P < 0.05$ was considered statistically significant.

List of Supplementary materials:

Materials and Methods

Fig. S1. Expression of AQP4 in mouse cardiac myocytes and *AQP* in PCM1-positive nuclear RNA from control and hypertrophic human myocardium.

Fig. S2. Afterload control in *Aqp1* mice under transverse aortic constriction or Angiotensin II infusion, and effect of Endothelin-1 on [^{14}C]-Phenylalanine incorporation in adult cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice.

Fig. S3. Fluorescence-based measurements of cell water intake in adult mouse cardiac myocytes exposed to hypo-osmotic buffer

Fig. S4. Reduced expression of pro-fibrotic mediators in *Aqp1*^{-/-} cardiac myocytes and of their paracrine effect in cardiac fibroblasts

Fig. S5. Protein sequence alignment using AQP1 as target.

Fig. S6. Effect of Bacopaside II on contractile properties of EHM with or without noradrenaline.

Fig. S7. Inhibitory effect of the standardized extract of *Bacopa monnieri* on AQP1-mediated water permeability in *Xenopus* oocytes.

Fig. S8. Schematic diagram summarizing the proposed mechanism of AQP1 inhibition by bacopaside II.

Table S1. Clinical characteristics of donors with normal vs. hypertrophic left ventricular remodeling

Table S2. Sequences of primers used in RT-qPCR

Data file S1. Individual subject-level data for main figures

Data file S2. Individual subject-level data for supplementary figures

References

1. R. Knoll, G. Iaccarino, G. Tarone, D. Hilfiker-Kleiner, J. Bauersachs, A. F. Leite-Moreira, P. H. Sugden, J. L. Balligand., Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC. *Eur J Heart Fail* **13**, 811-819 (2011).
2. A. P. Lourenco, A. F. Leite-Moreira, J. L. Balligand, J. Bauersachs, D. Dawson, R. A. de Boer, L. J. de Windt, I. Falcao-Pires, R. Fontes-Carvalho, S. Franz, M. Giacca, D. Hilfiker-Kleiner, E. Hirsch, C. Maack, M. Mayr, B. Pieske, T. Thum, C. G. Tocchetti, D. L. Brutsaert, S. Heymans, An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. *Eur J Heart Fail* **20**, 216-227 (2018).
3. Y. Ye, J. Li, Z. Yuan, Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials. *PLoS One* **8**, e56803 (2013).
4. G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, C. Gluud, Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* **297**, 842-857 (2007).
5. G. G. Schiattarella, F. Altamirano, D. Tong, K. M. French, E. Villalobos, S. Y. Kim, X. Luo, N. Jiang, H. I. May, Z. V. Wang, T. M. Hill, P. P. A. Mammen, J. Huang, D. I. Lee, V. S. Hahn, K. Sharma, D. A. Kass, S. Lavandro, T. G. Gillette, J. A. Hill, Nitrosative stress drives heart failure with preserved ejection fraction. *Nature* **568**, 351-356 (2019).
6. T. Munzel, G. G. Camici, C. Maack, N. R. Bonetti, V. Fuster, J. C. Kovacic, Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series. *J Am Coll Cardiol* **70**, 212-229 (2017).
7. B. Steinhorn, A. Sorrentino, S. Badole, Y. Bogdanova, V. Belousov, T. Michel, Chemogenetic generation of hydrogen peroxide in the heart induces severe cardiac dysfunction. *Nat Commun* **9**, 4044 (2018).

8. A. Arcaro, F. Pirozzi, A. Angelini, C. Chimenti, L. Crotti, C. Giordano, D. Mancardi, D. Torella, C. G. Tocchetti, Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. *Oxid Med Cell Longev* **2016**, 6353469 (2016).
9. P. Agre, The aquaporin water channels. *Proc Am Thorac Soc* **3**, 5-13 (2006).
10. V. Montiel, E. Leon Gomez, C. Bouzin, H. Esfahani, M. Romero Perez, I. Lobysheva, O. Devuyst, C. Dessy, J. L. Balligand, Genetic deletion of aquaporin-1 results in microcardia and low blood pressure in mouse with intact nitric oxide-dependent relaxation, but enhanced prostanoids-dependent relaxation. *Pflugers Arch* **466**, 237-251 (2014).
11. G. P. Bienert, F. Chaumont, Aquaporin-facilitated transmembrane diffusion of hydrogen peroxide. *Biochim Biophys Acta* **1840**, 1596-1604 (2014).
12. E. W. Miller, B. C. Dickinson, C. J. Chang, Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular signaling. *Proc Natl Acad Sci U S A* **107**, 15681-15686 (2010).
13. M. Bertolotti, S. Bestetti, J. M. Garcia-Manteiga, I. Medrano-Fernandez, A. Dal Mas, M. L. Malosio, R. Sitia, Tyrosine kinase signal modulation: a matter of H₂O₂ membrane permeability? *Antioxid Redox Signal* **19**, 1447-1451 (2013).
14. S. Watanabe, C. S. Moniaga, S. Nielsen, M. Hara-Chikuma, Aquaporin-9 facilitates membrane transport of hydrogen peroxide in mammalian cells. *Biochem Biophys Res Commun* **471**, 191-197 (2016).
15. B. Yang, Y. Song, D. Zhao, A. S. Verkman, Phenotype analysis of aquaporin-8 null mice. *Am J Physiol Cell Physiol* **288**, C1161-1170 (2005).
16. A. S. Verkman, Knock-out models reveal new aquaporin functions. *Handb Exp Pharmacol*, 359-381 (2009).
17. S. Al-Samir, Y. Wang, J. D. Meissner, G. Gros, V. Endeward, Cardiac Morphology and Function, and Blood Gas Transport in Aquaporin-1 Knockout Mice. *Front Physiol* **7**, 181 (2016).
18. T. L. Butler, C. G. Au, B. Yang, J. R. Egan, Y. M. Tan, E. C. Hardeman, K. N. North, A. S. Verkman, D. S. Winlaw, Cardiac aquaporin expression in humans, rats, and mice. *Am J Physiol Heart Circ Physiol* **291**, H705-713 (2006).
19. A. O. Verkerk, E. M. Lodder, R. Wilders, Aquaporin Channels in the Heart-Physiology and Pathophysiology. *Int J Mol Sci* **20**, (2019).

20. B. Thienpont, J. M. Aronsen, E. L. Robinson, H. Okkenhaug, E. Loche, A. Ferrini, P. Brien, K. Alkass, A. Tomasso, A. Agrawal, O. Bergmann, I. Sjaastad, W. Reik, H. L. Roderick, The H3K9 dimethyltransferases EHMT1/2 protect against pathological cardiac hypertrophy. *J Clin Invest* **127**, 335-348 (2017).
21. J. Yu, A. J. Yool, K. Schulten, E. Tajkhorshid, Mechanism of gating and ion conductivity of a possible tetrameric pore in aquaporin-1. *Structure* **14**, 1411-1423 (2006).
22. M. Kourghi, J. V. Pei, M. L. De Ieso, G. Flynn, A. J. Yool, Bumetanide Derivatives AqB007 and AqB011 Selectively Block the Aquaporin-1 Ion Channel Conductance and Slow Cancer Cell Migration. *Mol Pharmacol* **89**, 133-140 (2016).
23. J. V. Pei, M. Kourghi, M. L. De Ieso, E. M. Campbell, H. S. Dorward, J. E. Hardingham, A. J. Yool, Differential Inhibition of Water and Ion Channel Activities of Mammalian Aquaporin-1 by Two Structurally Related Bacopaside Compounds Derived from the Medicinal Plant *Bacopa monnieri*. *Mol Pharmacol* **90**, 496-507 (2016).
24. T. Munzel, T. Gori, J. F. Keaney, Jr., C. Maack, A. Daiber, Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. *Eur Heart J* **36**, 2555-2564 (2015).
25. A. Van Steenberghe, M. Balteau, A. Ginion, L. Ferte, S. Battault, C. M. Ravenstein, J. L. Balligand, E. P. Daskalopoulos, P. Gilon, F. Despa, S. Despa, J. L. Vanoverschelde, S. Horman, H. Koepsell, G. Berry, L. Hue, L. Bertrand, C. Beauloye, Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. *Sci Rep* **7**, 41166 (2017).
26. S. Altenhofer, K. A. Radermacher, P. W. Kleikers, K. Wingler, H. H. Schmidt, Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. *Antioxid Redox Signal* **23**, 406-427 (2015).
27. V. T. Dao, M. H. Elbatreek, S. Altenhofer, A. I. Casas, M. P. Pachado, C. T. Neullens, U. G. Knaus, H. Schmidt, Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. *Free Radic Biol Med* **148**, 60-69 (2020).
28. A. B. Fisher, Redox signaling across cell membranes. *Antioxid Redox Signal* **11**, 1349-1356 (2009).
29. K. Chen, S. E. Craige, J. F. Keaney, Jr., Downstream targets and intracellular compartmentalization in Nox signaling. *Antioxid Redox Signal* **11**, 2467-2480 (2009).

30. H. Kalwa, J. L. Sartoretto, R. Martinelli, N. Romero, B. S. Steinhorn, M. Tao, C. K. Ozaki, C. V. Carman, T. Michel, Central role for hydrogen peroxide in P2Y1 ADP receptor-mediated cellular responses in vascular endothelium. *Proc Natl Acad Sci U S A* **111**, 3383-3388 (2014).
31. N. Hermida, L. Michel, H. Esfahani, E. Dubois-Deruy, J. Hammond, C. Bouzin, A. Markl, H. Colin, A. V. Steenbergen, C. De Meester, C. Beauloye, S. Horman, X. Yin, M. Mayr, J. L. Balligand, Cardiac myocyte beta3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling. *European heart journal* **39**, 888-898 (2018).
32. G. P. Bienert, A. L. Moller, K. A. Kristiansen, A. Schulz, I. M. Moller, J. K. Schjoerring, T. P. Jahn, Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes. *J Biol Chem* **282**, 1183-1192 (2007).
33. M. Tiburcy, J. E. Hudson, P. Balfanz, S. Schlick, T. Meyer, M. L. Chang Liao, E. Levent, F. Raad, S. Zeidler, E. Wingender, J. Riegler, M. Wang, J. D. Gold, I. Kehat, E. Wettwer, U. Ravens, P. Dierickx, L. W. van Laake, M. J. Goumans, S. Khadjeh, K. Toischer, G. Hasenfuss, L. A. Couture, A. Unger, W. A. Linke, T. Araki, B. Neel, G. Keller, L. Gepstein, J. C. Wu, W. H. Zimmermann, Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. *Circulation* **135**, 1832-1847 (2017).
34. C. Stough, L. A. Downey, J. Lloyd, B. Silber, S. Redman, C. Hutchison, K. Wesnes, P. J. Nathan, Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. *Phytother Res* **22**, 1629-1634 (2008).
35. A. Dowell, G. Davidson, D. Ghosh, Validation of Quantitative HPLC Method for Bacosides in KeenMind. *Evid Based Complement Alternat Med* **2015**, 696172 (2015).
36. K. M. Holmstrom, T. Finkel, Cellular mechanisms and physiological consequences of redox-dependent signalling. *Nat Rev Mol Cell Biol* **15**, 411-421 (2014).
37. J. R. Burgoyne, H. Mongue-Din, P. Eaton, A. M. Shah, Redox signaling in cardiac physiology and pathology. *Circ Res* **111**, 1091-1106 (2012).
38. W. M. Nauseef, Detection of superoxide anion and hydrogen peroxide production by cellular NADPH oxidases. *Biochim Biophys Acta* **1840**, 757-767 (2014).

39. E. Schroder, P. Eaton, Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: issues and considerations. *Curr Opin Pharmacol* **8**, 153-159 (2008).
40. A. Almasalmeh, D. Krenc, B. Wu, E. Beitz, Structural determinants of the hydrogen peroxide permeability of aquaporins. *FEBS J* **281**, 647-656 (2014).
41. D. K. Chakravorty, B. Wang, M. N. Ucisik, K. M. Merz, Jr., Insight into the cation- π interaction at the metal binding site of the copper metallochaperone CusF. *J Am Chem Soc* **133**, 19330-19333 (2011).
42. K. S. C. Reid, P. F. Lindley, J. M. Thornton, Sulphur-aromatic interactions in proteins. *FEBS Letters* **190**, 209-213 (1985).
43. R. Bhattacharyya, D. Pal, P. Chakrabarti, Disulfide bonds, their stereospecific environment and conservation in protein structures. *Protein Eng Des Sel* **17**, 795-808 (2004).
44. B. A. Freeman, J. D. Crapo, Biology of disease: free radicals and tissue injury. *Lab Invest* **47**, 412-426 (1982).
45. A. K. Lewis, K. M. Dunleavy, T. L. Senkow, C. Her, B. T. Horn, M. A. Jersett, R. Mahling, M. R. McCarthy, G. T. Perell, C. C. Valley, C. B. Karim, J. Gao, W. C. Pomerantz, D. D. Thomas, A. Cembran, A. Hinderliter, J. N. Sachs, Oxidation increases the strength of the methionine-aromatic interaction. *Nat Chem Biol* **12**, 860-866 (2016).
46. D. Pal, P. Chakrabarti, Non-hydrogen bond interactions involving the methionine sulfur atom. *J Biomol Struct Dyn* **19**, 115-128 (2001).
47. S. Bestetti, I. Medrano-Fernandez, M. Galli, M. Ghitti, G. P. Bienert, G. Musco, A. Orsi, A. Rubartelli, R. Sitia, A persulfidation-based mechanism controls aquaporin-8 conductance. *Sci Adv* **4**, eaar5770 (2018).
48. K. Madhusudan Makwana, R. Mahalakshmi, Implications of aromatic-aromatic interactions: From protein structures to peptide models. *Protein Sci* **24**, 1920-1933 (2015).
49. E. Cauet, M. Rومان, R. Wintjens, J. Lievin, C. Biot, Histidine-Aromatic Interactions in Proteins and Protein-Ligand Complexes: Quantum Chemical Study of X-ray and Model Structures. *J Chem Theory Comput* **1**, 472-483 (2005).
50. M. Lo Conte, K. S. Carroll, The redox biochemistry of protein sulfenylation and sulfinylation. *J Biol Chem* **288**, 26480-26488 (2013).

51. S. H. Kwon, D. R. Pimentel, A. Remondino, D. B. Sawyer, W. S. Colucci, H₂O₂ regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. *J Mol Cell Cardiol* **35**, 615-621 (2003).
52. F. H. Messerli, S. F. Rimoldi, S. Bangalore, The Transition From Hypertension to Heart Failure: Contemporary Update. *JACC Heart Fail* **5**, 543-551 (2017).
53. T. Ma, B. Yang, A. Gillespie, E. J. Carlson, C. J. Epstein, A. S. Verkman, Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels. *J Biol Chem* **273**, 4296-4299 (1998).
54. G. Esposito, A. Rapacciuolo, S. V. Naga Prasad, H. Takaoka, S. A. Thomas, W. J. Koch, H. A. Rockman, Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. *Circulation* **105**, 85-92 (2002).
55. A. Russo, F. Borrelli, Bacopa monniera, a reputed nootropic plant: an overview. *Phytomedicine* **12**, 305-317 (2005).
56. C. Kongkeaw, P. Dilokthornsakul, P. Thanarangsarit, N. Limpeanchob, C. Norman Scholfield, Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. *J Ethnopharmacol* **151**, 528-535 (2014).
57. D. Mathur, K. Goyal, V. Koul, A. Anand, The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (Bacopa monniera). *Front Pharmacol* **7**, 44 (2016).
58. E. Migliati, N. Meurice, P. DuBois, J. S. Fang, S. Somasekharan, E. Beckett, G. Flynn, A. J. Yool, Inhibition of aquaporin-1 and aquaporin-4 water permeability by a derivative of the loop diuretic bumetanide acting at an internal pore-occluding binding site. *Mol Pharmacol* **76**, 105-112 (2009).
59. A. J. Yool, J. Morelle, Y. Cnops, J. M. Verbavatz, E. M. Campbell, E. A. Beckett, G. W. Booker, G. Flynn, O. Devuyt, AqF026 is a pharmacologic agonist of the water channel aquaporin-1. *J Am Soc Nephrol* **24**, 1045-1052 (2013).
60. B. A. Baghbaderani, X. Tian, B. H. Neo, A. Burkall, T. Dimezzo, G. Sierra, X. Zeng, K. Warren, D. P. Kovarcik, T. Fellner, M. S. Rao, cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications. *Stem Cell Reports* **5**, 647-659 (2015).

61. P. L. Soong, M. Tiburcy, W. H. Zimmermann, Cardiac differentiation of human embryonic stem cells and their assembly into engineered heart muscle. *Curr Protoc Cell Biol* **Chapter 23**, Unit23 28 (2012).
62. E. Krissinel, K. Henrick. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. *Acta Crystallogr D Biol Crystallogr.* **60**, 2256-2268 (2014).
63. H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, The Protein Data Bank. *Nucleic Acids Res* **28**, 235-242 (2000).
64. A. Waterhouse, M. Bertoni, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, F. T. Heer, T. A. P. de Beer, C. Rempfer, L. Bordoli, R. Lepore, T. Schwede, SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res* **46**, W296-W303 (2018).
65. M. Pellegrini-Calace, T. Maiwald, J. M. Thornton, PoreWalker: a novel tool for the identification and characterization of channels in transmembrane proteins from their three-dimensional structure. *PLoS Comput Biol* **5**, e1000440 (2009).
66. Y. Dehouck, J. M. Kwasigroch, D. Gilis, M. Rooman, PoPMuSiC 2.1: a web server for the estimation of protein stability changes upon mutation and sequence optimality. *BMC Bioinformatics* **12**, 151 (2011).
67. K. G. Tina, R. Bhadra, N. Srinivasan, PIC: Protein Interactions Calculator. *Nucleic Acids Res* **35**, W473-476 (2007).
68. R. Wintjens, J. Lievin, M. Rooman, E. Buisine, Contribution of cation-pi interactions to the stability of protein-DNA complexes. *J Mol Biol* **302**, 395-410 (2000).
69. O. Bergmann, S. Jovinge, Isolation of cardiomyocyte nuclei from post-mortem tissue. *J Vis Exp* **65**, 4205 (2012).
70. O. Bergmann, S. Zdunek, K. Alkass, H. Druid, S. Bernard, J. Frisen, Identification of cardiomyocyte nuclei and assessment of ploidy for the analysis of cell turnover. *Exp Cell Res* **317**, 188-194 (2011).
71. C. Kulahoglu, A. Brautigam, Quantitative transcriptome analysis using RNA-seq. *Methods Mol Biol* **1158**, 71-91 (2014).
72. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
73. W. Huang da, B. T. Sherman, R. A. Lempicki, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* **37**, 1-13 (2009).

74. W. Huang da, B. T. Sherman, R. A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44-57 (2009).
75. X. Jiao, B. T. Sherman, W. Huang da, R. Stephens, M. W. Baseler, H. C. Lane, R. A. Lempicki, DAVID-WS: a stateful web service to facilitate gene/protein list analysis. *Bioinformatics* **28**, 1805-1806 (2012).
76. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, F. Speleman, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol* **3**, RESEARCH0034 (2002).
77. N. Hermida, A. Markl, J. Hamelet, T. Van Assche, A. Vanderper, P. Herijgers, M. van Bilsen, D. Hilfiker-Kleiner, G. Noppe, C. Beauloye, S. Horman, J. L. Balligand, HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. *Cardiovasc Res* **99**, 44-54 (2013).
78. F. Aboubakar Nana, D. Hoton, J. Ambroise, M. Lecocq, M. Vanderputten, Y. Sibille, B. Vanaudenaerde, C. Pilette, C. Bouzin, S. Ocak, Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer. *Cancers (Basel)* **11**, 1526 (2019).
79. F. J. Alvarez-Leefmans, J. J. Herrera-Perez, M. S. Marquez, V. M. Blanco, Simultaneous measurement of water volume and pH in single cells using BCECF and fluorescence imaging microscopy. *Biophys J* **90**, 608-618 (2006).
80. M. R. Ruggiero, S. Baroni, S. Pezzana, G. Ferrante, S. Geninatti Crich, S. Aime, Evidence for the Role of Intracellular Water Lifetime as a Tumour Biomarker Obtained by In Vivo Field-Cycling Relaxometry. *Angew Chem Int Ed Engl* **57**, 7468-7472 (2018).
81. M. R. Ruggiero, S. Baroni, S. Aime, S. Geninatti Crich, Relaxometric investigations addressing the determination of intracellular water lifetime: a novel tumour biomarker of general applicability. *Mol Phys* **117**, 968-974 (2019).
82. M. Balteau, A. Van Steenberghe, A. D. Timmermans, C. Dessy, G. Behets-Wydemans, N. Tajeddine, D. Castanares-Zapatero, P. Gilon, J. L. Vanoverschelde, S. Horman, L. Hue, L. Bertrand, C. Beauloye, AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. *Am J Physiol Heart Circ Physiol* **307**, H1120-1133 (2014).

Acknowledgments:

We thank A. Daumerie and F. Aboubakar for help with the tyramide staining (for the human myocardial tissue immunohistochemistry), H. Chae for helping with the laser-confocal fluorescence microscopy measurements, S. Baroni and M. Russo for helping with the ¹H-NMR relaxometric experiments, Y. Cnops and S. Druart for handling of the *Aqp1* mice, J. V. Pei for contributing in silico modelling expertise, A. Van Steenberghe, J. Dontaine, C. Dufey and C. de Meester for help with handling the human myocardial biopsies. Generation of the GMP line LiPSC-GR1.1 was supported by the NIH Common Fund Regenerative Medicine Program. The NIH Common Fund and the National Center for Advancing Translational Sciences (NCATS) are joint stewards of the LiPSC-GR1.1 resource.

Funding:

Work supported by Grants CR J023516F from FRS-FNRS, AGR X100218F and X500220F from Welbio, ARC1621-074 from Federation Wallonie Bruxelles to JLB. S.H. is Senior Research Associate and L.B., J.C.J and P.G. are Research Directors from FRS-FNRS, Belgium. C.B. was a clinical Master Specialist from FRS-FNRS, Belgium. LYMM and CF are “Chargé de Recherche” of the FRS-FNRS, Belgium. Work in the HLR laboratory is supported by an Odysseus grant (90663) from Research Foundation Flanders (FWO). Work in the AY laboratory is supported by Australian Research Council grant 19ARC_DP190101745. O.B. is supported by the Center for Regenerative Therapies Dresden, the Karolinska Institutet, the Swedish Research Council, the Ragnar Söderberg Foundation, and the Åke Wiberg Foundation. OD is supported by the ARC1621-074 from Federation Wallonie Bruxelles, the Swiss National Centre of Competence in Research Kidney Control of Homeostasis (NCCR Kidney.CH) program and the Swiss National Science Foundation (310030_189044). W.H.Z. and M.T. are supported by the DFG (German Research Foundation: EXC 2067/1, SFB1002 C04 and S01), the DZHK (German Center for Cardiovascular research), and the Fondation Leducq. Additional funding was provided by the National Institute on Aging of the National Institutes of Health Grant R21 AG06307; Brigham and Women’s Hospital Health and Technology Innovation Award; and Brigham Biomedical Research Institute Fund to Sustain Research Excellence. L.B. and J.L.B. are Investigators of the WELBIO Institute.

Author contribution:

J.-L.B. conceived the original hypothesis, J.-L.B., V.M. conceived the experiments with input from O.D., and J.-L.B. supervised the project.

J.-L.B. and V.M. planned the experiments and analyzed the results.

V.M., H.E. and D.D.M. carried out the core of the experiments.

E.L.R. carried out the RNA-Seq and RT-qPCR on the hypertrophic human samples, and analyzed the output with H.L.R.

R.B. performed the structural analysis and interpreted the data with D.G and M.R.

L.Y.M.M measured specific transcript levels in mouse and human tissues with S.H.

B.S. and T.M. developed and provided the HyPer3 biosensor and experimental protocols

J.-P.D, V.M. and D.D.M performed the HyPer3 measurements and analyzed them with J.-C.J.

R.B. and D.D.M. carried out the osmotic myocyte volume experiments with P.G.

D.D.M., V.M., A.G. and S.G-C performed the ¹H-NMR relaxometry experiments

M.T. carried out the experiments on iPSC and EHM, and analyzed them with W.H.Z.

P.H.C carried out the oocytes swelling assays and analyzed them with A.Y.

H.E. and C.F. performed echocardiographic measurements with guidance from Ch.B.

D.D.M., V.M. and C.F. performed immunoblotting and protein synthesis assays with guidance from L.B.

D.D.M. and V.M. performed the PLA assays with the help of Ca.B.

F.D.Z performed red blood cells measurements with the help of D.B.

H.D. expanded and provided the *Aqp1* mice under the supervision of O.D.

O.B. provided cadaveric human cardiac tissue and advice on myocyte nuclei isolation

J.-L.V. provided patient cardiac biopsies and clinical echocardiographic data

V.M. and J.-L.B wrote the manuscript

L.Y.M.M worked on illustration of the data

All authors discussed the results, provided critical feedback, contributed to the writing or commented on the manuscript.

Competing interests: Authors have no competing interests

Data and materials availability: All data associated with this study are available in the main text or the supplementary materials. All the data of RNAseq have been registered and submitted to the EMBL-EBI European Nucleotide Archive (ENA) with accession number PRJEB36807.

Figure Legends

Fig. 1. Expression of aquaporin-1 in human and mouse cardiac myocytes and relationship to hypertrophy.

(A) Representative image of AQP1 immunostaining in adult mouse cardiac myocytes (red staining: AQP1; green staining: α -sr-actinin; blue staining: DAPI). Neg CTL: absent immunostaining after omission of primary anti-AQP1 antibody in presence of the secondary anti-IgG antibody. Scale bar 50 μ M. (B) Quantification of *AQP* expression as reads per kilobase per million reads (RPKM) from RNA-seq data of transcripts from PCM1-positive nuclei (cardiac myocytes) isolated from healthy control (open circles) and left ventricle (LV) hypertrophic myocardium (closed circles) (Mean $\pm$ SEM; N=4 independent experiments, each running a healthy and a hypertrophic sample in parallel). Intronic and exonic reads counted. (C) Human total heart mass as measured post-mortem (table S1; N=5 subjects each). (D) *AQP1* mature mRNA expression in healthy vs LV hypertrophic PCM1-positive nuclei as measured by RT-qPCR and normalized to the geometric mean of *GAPDH*, *ACTB* and *B2M*. Each dot is representative of triplicate measurements by RT-qPCR; N= 5 patients each, from C. * $P < 0.05$ by Student's t-test. (E) Representative histological section of human LV healthy (upper) and hypertrophic (lower) myocardium from a patient with aortic stenosis (green staining: AQP1; red staining: WGA; blue staining: DAPI), scale bar 10 μ M. Neg Ctl is immunostaining without primary AQP1 antibody in presence of secondary antibody. (F) Correlation between abundance of human *AQP1* transcripts in biopsy samples of LV myocardium and LV mass, measured pre-operatively by echocardiography. Each dot is representative of triplicate measurements by RT-qPCR (normalized to *GAPDH*); N= 26 patients.

Fig. 2. Aquaporin-1 deletion attenuates myocardial hypertrophy and fibrosis. (A-I) Morphometric and histologic

assessment of remodeling in *Aqp1*^{+/+}, *Aqp1*^{+/-} and *Aqp1*^{-/-} mice subjected to TAC or sham for 3 weeks. (N mice indicated in bars or below the x-axis). (A) Hematoxylin and eosin staining of longitudinal sections of hearts from mice of different genotypes after TAC or sham operation; scale bar: 1 mm. (B) Left ventricular (LV) mass normalized to tibial length (TL). (C) Myocyte transverse area measured histologically (WGA staining; each dot is mean from >200 myocytes/heart). (D) Interstitial fibrosis (Picosirius red staining; % section area; each dot is mean from 3 sections/heart). (E) Quantification of collagen content using polarized light microscopy on picosirius red stained heart sections from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice subjected to TAC or sham operation. Representative images and

quantification of the total collagen content and proportion of collagen fibers defined by color hue, representing the relative increase in collagen thickness and packing/alignment from yellow to red. (F) Quantification of COL1A1 protein by immunostaining (each dot is mean from 3 sections/heart) (G-H) Hypertrophic transcriptional program assessed by (G) *Nppb* mRNA abundance (RT-qPCR) or (H) relative *Myh7/Myh6* mRNA abundance (RT-qPCR). (I) Representative histological section of LV myocardium of *Aqp1*^{+/+} and *Aqp1*^{-/-} mice 3 weeks after TAC or sham (green staining: isolectin; red staining: WGA), scale 20 μ M. (J-L) Morphometric and histologic assessment of remodeling in *Aqp1*^{+/+} and *Aqp1*^{-/-} mice subjected to minipump infusion of Angiotensin II (AGII; 2 mg/kg/day) or physiological solution for 14 days (N mice indicated in bars or below the x-axis). (J) LV mass normalized to tibial length. (K) Myocyte transverse area measured histologically (WGA staining; each dot is mean from >200 myocytes/heart). (L) Interstitial fibrosis (Picrosirius red staining; % section area; each dot is mean from 3 sections/heart). Mean $\pm$ SEM; * $P<0.05$ vs solvent ctl; # $P<0.05$ vs. AGII or TAC by two-way ANOVA followed by Tukey's correction for multiple comparisons, except (H): * $P<0.05$ by Kruskal-Wallis, corrected for multiple comparisons with Dunn's test and (F and J): * $P<0.05$ by one-way ANOVA, corrected for multiple comparisons with Sidak's test.

Figure 3. The intra-subunit pore, but not the central channel, of aquaporin-1 is necessary for hypertrophy but not for rapid water movements in cardiac myocytes

(A) Representative microscopic images of single adult cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice exposed in vitro to angiotensin II (AGII), endothelin-1 (ET-1), isoproterenol (ISO), phenylephrine (PE), or physiological solution for 18 hours and stained for alpha-sarcomeric-actinin for cell surface measurements; scale 30 μ M. (B-E) Cell surface area of cardiac myocytes treated with AGII (B), ET-1 (C), ISO (D) or PE (20-50 μ M, E). Each dot is mean of 30-70 cells/culture/condition, from independent preparations; N=3 animals from each genotype. (F) Comparative effects of AqB011 (central channel inhibitor), HgCl₂ and Bacopaside II (both blockers of the intra-subunit water channel) on the pro-hypertrophic effect of PE in isolated cardiac myocytes cultured as above. Mean $\pm$ SEM of 30-70 cells/culture/condition from independent preparations; N=5 animals from each genotype. * $P<0.05$ compared to solvent-treated *Aqp1*^{+/+}, # $P<0.05$ compared to agonist-treated *Aqp1*^{+/+} by two-way ANOVA followed by Tukey correction for multiple testing except (F) in one-way ANOVA compared to solvent-treated *Aqp1*^{+/+}. (G) Comparative

increase in cell volume (V_t/V_0) of *Aqp1*^{+/+} and *Aqp1*^{-/-} myocytes (n=8 *Aqp1*^{+/+} and 8 *Aqp1*^{-/-} myocytes from 2 independent preparations) exposed to hypo-osmotic (100 mOsm l⁻¹) buffer, measured by confocal fluorescence microscopy. **(H)** Comparative increase in water residence time (τ_{in}) under hypo-osmotic stress (100 mOsm l⁻¹) in *Aqp1*^{+/+} and *Aqp1*^{-/-} myocyte preparations (from N=6 and 4 *Aqp1*^{+/+} mice in iso-osmotic or hypo-osmotic condition, respectively; N=4 *Aqp1*^{-/-} mice in both conditions) measured by ¹H-NMR relaxometry. **(I)** Comparative increase in cell volume (V_t/V_0) of *Aqp1*^{+/+} and *Aqp1*^{-/-} myocytes (n=14 and 16, respectively from 3 *Aqp1*^{+/+} and 4 *Aqp1*^{-/-} mice) exposed to phenylephrine (50 μ M). **(G-I)** Mean $\pm$ SEM; $P < 0.05$ compared to iso-osmotic or control condition in each genotype; no difference between genotypes by two-way ANOVA with Sidak correction for multiple comparisons.

Figure 4. NOX2-p47^{phox} colocalizes with aquaporin-1 at the plasma membrane and mediates cardiac myocyte hypertrophy upon stimulation with Angiotensin II

(A) Representative images of proximity ligation assay (PLA) showing colocalization of p47^{phox} and CAV3 at the membrane of adult cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice, with or without angiotensin II (AGII, 1 μ M). PLA was performed 30 min after AGII addition. Note that deletion of AQP1 does not prevent the recruitment of p47^{phox} upon AGII treatment. Neg Ctl 1: absence of PLA signal after omission of anti-p47^{phox} primary Ab; Neg Ctl 2: absence of PLA signal after omission of anti-CAV3 primary Ab. Scale bar: 50 μ M. The experiment was repeated in 3 different preparations with similar results (N=3). **(B)** (Upper) Representative image of PLA showing co-localization of p47^{phox} and AQP1 in adult cardiac myocytes from *Aqp1*^{+/+} mice treated or not with AGII (1 μ M). PLA was performed 30 min after AGII. Scale bar: 50 μ M. Negative controls in *Aqp1*^{-/-} myocytes (Neg Ctl 1) or *Aqp1*^{+/+} myocytes incubated with secondary Abs (but in absence of one of the primary Abs; Neg Ctl 2) are shown in parallel; (Lower) Quantification of PLA expressed in dots per cardiac myocyte in *Aqp1*^{+/+} myocytes, from independent preparations; Mean $\pm$ SEM; N=3. * $P < 0.05$ by Mann-Whitney test. **(C)** Effect of VAS2870, a pan-NOX inhibitor (at 0.77 μ M, i.e. IC₅₀ for NOX2 inhibition) incubated for 18 h on the hypertrophic response of adult cardiac myocytes from *Aqp1*^{+/+} mice exposed to pro-hypertrophic agonists (in vitro, 18h). Each dot is mean cell surface area from 30-

70 cells/culture/condition from independent preparations; Mean±SEM; N=3 *Aqp1*^{+/+} mice. * *P*<0.05 compared to ctrl by one-way ANOVA followed by Dunnett's correction for multiple comparisons.

Fig. 5. Aquaporin-1 modulates the pro-hypertrophic signaling mediated by extracellular H₂O₂

(A-B) Effect of extracellular (non-PEGylated) catalase (incubated for 2 or 20 hours) on the hypertrophic response of cultured adult (A) or neonatal (B) murine cardiac myocytes to phenylephrine (PE, in vitro, 18 h). Mean±SEM of 30-70 cells/condition per mouse. (A) N=4 adult *Aqp1*^{+/+} and *Aqp1*^{-/-} mice each and 3 *Aqp1*^{+/-} mice. (B) N=3 preparations from each genotype. * *P*<0.05 by two-way ANOVA, followed by Tukey's correction for multiple comparisons; (C-E) Comparative time-dependent phospho-immunoblotted signals for P-ERK (C,D) in membrane protein extracts from isolated adult cardiac myocytes from *Aqp1*^{+/+} mice with or without incubation with extracellular catalase (C) or from *Aqp1*^{-/-} mice (D), exposed in vitro to PE; (C,D) representative phosphoblots; (E) densitometric data. Mean±SEM; N=8 preparations from *Aqp1*^{+/+}, 4 from *Aqp1*^{+/+} with catalase and 4 from *Aqp1*^{-/-} mice). * *P*<0.05 compared to time 0 by one-way ANOVA, followed by Dunnett test for multiple comparisons. (F-G) Comparative time-dependent phospho-immunoblotted signals for P-p38MAPK in membrane protein extracts from isolated adult cardiac myocytes from *Aqp1*^{+/+} or *Aqp1*^{-/-} mice, exposed in vitro to PE. (F) Representative phosphoblot; (G) densitometric data. Mean±SEM; N=5 mice from each genotype. * *P*<0.05 compared to time 0 by one-way ANOVA, followed by Dunnett test for multiple comparisons.

Fig. 6. Aquaporin-1 mediates the facilitated transport of H₂O₂ in mouse cardiac myocytes

(A-B) Comparative increase in intracellular reactive oxidant species (ROS, measured by DCFDA fluorescence) in isolated adult cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice after time-dependent exposure to extracellular H₂O₂ (A, at 50 μM; B, at 100 μM); independent preparations from N=6 *Aqp1*^{+/+} and 4 *Aqp1*^{-/-} mice. (C) Comparative concentration-dependent increase in H₂O₂-specific HyPer3 fluorescence ratio (measured with a caveolae-targeted sensor) in isolated adult cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice exposed to extracellular H₂O₂. Mean of 10 cells each from N=6 *Aqp1*^{+/+} and 6 *Aqp1*^{-/-} mice. Note the absence of signal in cardiac myocytes expressing the SyPher2 probe (insensitive to H₂O₂). (D) Concentration-dependent inhibitory effect of the Aqp1 water channel blocker, Bacopaside II, on intracellular ROS (DCFDA fluorescence) of *Aqp1*^{+/+} adult cardiac myocytes exposed to

extracellular H₂O₂ (50 μ M); independent preparations from N=4 *Aqp1*^{+/+} mice. **(E-F)** Comparative increase in intracellular ROS (DCFDA fluorescence) in isolated adult cardiac myocytes from *Aqp1*^{+/+} and *Aqp1*^{-/-} mice after time-dependent exposure to extracellular phenylephrine (PE; **E**, 5 μ M; **F**, 50 μ M); independent preparations from N=8 *Aqp1*^{+/+} and 6 *Aqp1*^{-/-} mice. Mean $\pm$ SEM; * or # *P* < 0.05 compared to *Aqp1*^{+/+} by two-way ANOVA for repeated measures followed by Sidak correction for multiple comparisons.

Fig. 7. Human aquaporin-1 transports H₂O₂ and regulates the hypertrophy of human cardiac myocytes

(A) Graphical representation of the pore in human AQP1, rat AQP1 (modelled with 4csk as template), human AQP8 (modelled with 5i32 as template) and human AQP4: critical residues lining the pore of the water channel are represented (see text for details). **(B)** Inhibition of H₂O₂-induced fluorescence increase in human AQP1-expressing erythrocytes by the AQP1 water channel blocker, Bacopaside II. DCFDA-loaded human erythrocytes were exposed to extracellular H₂O₂ and fluorescence measured by FACS. Mean $\pm$ SEM; N=8 volunteers; * *P* < 0.05 compared to each control group without Bacopaside II (two-way ANOVA with Tukey correction for multiple comparisons). **(C)** Comparative expression of *AQP1* transcripts (by RNAseq) in human induced pluripotent stem cells (iPSC; N=3; minimal signal equated to 0), differentiated human engineered heart muscle cells (EHM; N=4), human fetal (N=3) and adult heart muscle (N=4). **(D)** Inhibition of noradrenaline (NA)-induced hypertrophy in human EHM by Bacopaside II. EHM were matured for 2 weeks and subsequently subjected to NA exposure for 1 week with or without Bacopaside II (10 μ M); cardiac myocyte size was determined by flow cytometry after enzymatic dispersion of EHM (n=min. 10 000 cells counted per EHM; 6 EHM per condition from 2 separate experimental series; Mean $\pm$ SEM; **P* < 0.05 vs. vehicle; # *P* < 0.05 vs. NA-treated EHM in absence of Bacopaside, two-way ANOVA with Tukey correction for multiple comparisons). **(E)** Contractile properties of human EHM after treatments as in **(D)** and assessed by measurements of force-frequency relationship (Bowditch effect) upon gradual increase of frequency of electrical

stimulation from 1 Hz to 3 Hz; FOC: Force of Contraction, normalized to values obtained at 1 Hz for each EHM; Mean $\pm$ SEM; 8 EHM per condition from 2 separate experiments.

Fig. 8. A standardized extract of *Bacopa monnieri* inhibits the intra-subunit water channel of human aquaporin-1 and attenuates cardiac hypertrophy in vivo

(A-C) Dose-dependent inhibition by the Bacopa extract (BE) of osmotic water permeability in *Xenopus* oocytes expressing human AQP1 channels. (A) Volumes of AQP1-expressing oocytes as a function of time after introduction into 50% hypotonic saline at time zero, standardized as a percentage of the initial volume. Data are mean $\pm$ SEM for $n=4$ oocytes per treatment group. (B) Comparative inhibitory effects of Bacopaside II and the Bacopa extract, added during a second swelling assay. Relative block was calculated per oocyte from the difference in swelling rates between the first (untreated) and second hypotonic assays, divided by the rate in the first assay. Data are mean $\pm$ SEM; values from (n) oocytes are above the x-axis. (C) Histogram summary of swelling rates in the first untreated assay (S1) and the second post-incubation assay (S2) conditions. Values from (n) oocytes are below the x-axis; differences analyzed by ANOVA ($P < 0.0001$), and post-hoc paired one-way T-tests ($*P < 0.05$). (D-G) Oral administration of the Bacopa extract attenuates Angiotensin II (AGII)-induced cardiac hypertrophy. Mice fed with the BE (1600 mg/kg, or 2400 mg/kg, or inactive excipient, were treated with osmotic minipump infusion of AGII (2 mg/kg/d) for 2 weeks, then euthanized for measurements of (D) left ventricle weight, normalized to tibial length. (E) Myocyte surface area (after WGA staining; each dot is mean from >200 myocytes/heart). (F) Fibrosis (Picrosirius red staining; % section area; each dot is mean from 3 sections/heart). (G) Collagen content using polarized light microscopy on picrosirius red stained heart sections; values from (N) mice as indicated in bars or below the x-axis; $*P < 0.05$ compared to untreated ctrl, by one-way ANOVA followed by Tukey's correction for multiple testing.

Table 1. Echocardiographic parameters in *Aqp1*^{+/+} and *Aqp1*^{-/-} mice submitted to transverse aortic constriction for 3 or 9 weeks. Results are mean $\pm$ SEM. Mixed-effect model with repeated measures (Tukey post-hoc test for TAC effect; Sidak post-hoc test for genotype effect). * $P < 0,05$ compared to pre-op measure in the same genotype; # $P < 0,05$ compared to pre-op measure of other genotype; \$ $P < 0,05$ compared to post-op measure of other genotype. TAC: transverse aortic constriction; HR: heart rate; LVEDv: left ventricle end-diastolic volume; LVESv: left ventricle end-systolic volume; EF: ejection fraction; IVSd: Interventricular septum thickness in diastoly; LVIDd: left ventricle internal diameter in diastoly; PWd: posterior wall thickness in diastoly; FS: fractional shortening; RWT: relative wall thickness; LVmass: left ventricular mass; Ao vel: (trans-gradient) aortic velocity

	WT			AQP1 KO		
	Pre-op (n=16)	TAC 3 weeks (n=7)	TAC 9 weeks (n=9)	Pre-op (n=16)	TAC 3 weeks (n=7)	TAC 9 weeks (n=9)
HR (bpm)	401 $\pm$ 8	379 $\pm$ 14	363 $\pm$ 17 *	355 $\pm$ 11 #	340 $\pm$ 15	377 $\pm$ 12
LVEDv (μ l)	74,8 $\pm$ 2,2	70,5 $\pm$ 3,9	67,7 $\pm$ 2,8	60,3 $\pm$ 3,0 #	64,9 $\pm$ 4,1	58,0 $\pm$ 1,8
LVESv (μ l)	40,7 $\pm$ 2,6	40,5 $\pm$ 4,6	35,6 $\pm$ 1,4	31,0 $\pm$ 2,6 #	34,8 $\pm$ 2,6	31,6 $\pm$ 2,2
EF (%) B-mode	46,2 $\pm$ 2,2	43,1 $\pm$ 4,0	47,2 $\pm$ 1,7	49,5 $\pm$ 2,6	46,2 $\pm$ 2,6	45,8 $\pm$ 2,9
IVSd (mm)	0,83 $\pm$ 0,03	0,97 $\pm$ 0,04 *	0,97 $\pm$ 0,05 *	0,68 $\pm$ 0,01 #	0,82 $\pm$ 0,07 *	0,82 $\pm$ 0,04 *\$
LVIDd (mm)	4,20 $\pm$ 0,04	4,14 $\pm$ 0,08	4,14 $\pm$ 0,08	4,02 $\pm$ 0,13	3,94 $\pm$ 0,13	3,94 $\pm$ 0,09
PWd (mm)	0,78 $\pm$ 0,03	1,03 $\pm$ 0,05 *	0,91 $\pm$ 0,02 *	0,68 $\pm$ 0,02	0,90 $\pm$ 0,10 *	0,82 $\pm$ 0,05 *
FS (%) M-mode	21,5 $\pm$ 1,1	21,5 $\pm$ 2,6	22,0 $\pm$ 1,0	23,7 $\pm$ 1,5	23,8 $\pm$ 2,2	21,0 $\pm$ 1,5
RWT	0,39 $\pm$ 0,01	0,48 $\pm$ 0,02 *	0,46 $\pm$ 0,01 *	0,34 $\pm$ 0,01	0,44 $\pm$ 0,05 *	0,42 $\pm$ 0,02 *
LV mass (mg)	128,9 $\pm$ 5,0	168,9 $\pm$ 8,4 *	157,2 $\pm$ 11,2 *	95,9 $\pm$ 3,6 #	128,9 $\pm$ 20,1 *\$	120,5 $\pm$ 10,9 \$
Ao vel. (m/s)	/	3,82 $\pm$ 0,34	2,68 $\pm$ 0,19	/	3,39 $\pm$ 0,44	2,68 $\pm$ 0,24

Table 2. Echocardiographic parameters in *Aqp1*^{+/+} and *Aqp1*^{-/-} mice submitted to osmotic minipump infusion of Angiotensin II. Results are mean ± SEM. 2 way-ANOVA for repeated measures (Sidak post-hoc test). * *P*<0,05 compared to pre-op measure of the same genotype; # *P*<0,05 compared to pre-op measure of other genotype; \$ *P*<0,05 compared to post-op measure of other genotype.

AngII 2 weeks				
	WT (16)		AQP1 KO (7)	
	Pre-op	2 weeks	Pre-op	2 weeks
HR (bpm)	388 ± 8	464 ± 8 *	420 ± 12 #	449 ± 10
LVEDv (μl)	62,8 ± 2,4	34,6 ± 3,0 *	49,6 ± 2,2 #	37,9 ± 1,8 *
LVESv (μl)	29,7 ± 1,7	15,1 ± 1,8 *	17,7 ± 1,3 #	16,0 ± 1,6
EF (%) B-mode	52,7 ± 1,8	57,3 ± 2,2	64,6 ± 2,1 #	58,2 ± 2,7
IVSd (mm)	0,82 ± 0,02	1,06 ± 0,05 *	0,71 ± 0,03	0,84 ± 0,04 \$*
LVIDd (mm)	3,99 ± 0,06	3,09 ± 0,11 *	3,64 ± 0,07 #	3,31 ± 0,07 *
PWd (mm)	0,84 ± 0,03	1,20 ± 0,07 *	0,72 ± 0,03	0,92 ± 0,05 \$*
FS (%) M-mode	26,9 ± 1,2	36,2 ± 2,0 *	35,5 ± 1,7 #	31,5 ± 1,7
RWT	0,42 ± 0,01	0,77 ± 0,06 *	0,39 ± 0,02	0,54 ± 0,03 \$
LV mass (mg)	123,6 ± 3,7	129,6 ± 5,2	86,1 ± 4,5 #	99,1 ± 4,6 \$

Figure 1

Figure 2

Figure 3

A

B

C

D

E

F

G

H

I

Figure 4

Figure 5

Figure 6

Figure 7

A

B

C

D

E

Figure 8

"This manuscript has been accepted for publication in Science Translational Medicine. This version has not undergone final editing. Please refer to the complete version of record at <https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.sciencetranslationalmedicine.org%2F&data=02%7C01%7Cjean-luc.balligand%40uclouvain.be%7C7d55d1acf0f448e46ad808d84dd5eedc%7C7ab090d4fa2e4ecfbc7c4127b4d582ec%7C0%7C0%7C637344929377642826&sdata=ZNPHcw5LcAQZLNiSvGFdq6CVmYCGP1NS2daOqefA4Eg%3D&reserved=0>. The manuscript may not be reproduced or used in any manner that does not fall within the fair use provisions of the Copyright Act without the prior written permission of AAAS."